Citations

Clear

1526 citation(s) found for "Sun, Bo".

Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
Tefferi, Ayalew , Verstovšek, Srđan , Passamonti, Francesco , Gisslinger, Heinz , Paquette, Ronald , Cervantes, Francisco , Rivera, Candido E., Deeg, H. Joachim , Thiele, Jüergen, Kvasnicka, H. M. , Vardiman, James W., Zhang, Yanming , Bekele, B. Nebiyou , Kantarjian, Hagop M. , Barosi, Giovanni , Roboz, Gail J. , Mesa, Ruben A. , Gale, Robert Peter , Verstovsek, Srdan , Passamonti, Francesco , Kantarjian, Hagop

Mayo Clinic

Journal of Clinical Oncology | August 4, 2009 | Volume: 27 | Issue: 27 | Pages: 4563-4569

10.1200/jco.2008.21.7356 | PMID 19652059 Get It

Purpose Thalidomide and lenalidomide can alleviate anemia in myelofibrosis. However, their value is undermined by their respective potential to cause peripheral neuropathy and myelosuppression. We therefore evaluated the safety and therapeutic activity of another immunomodulatory drug, pomalidomide. Methods In a phase II randomized, multicenter, double-blind, adaptive design study, four treatment arms were evaluated: pomalidomide (2 mg/d) plus placebo, pomalidomide (2 mg/d) plus prednisone, pomalidomide (0.5 mg/d) plus prednisone, and prednisone plus placebo. Pomalidomide was administered for up to 12 28-day treatment cycles. Prednisone (30 mg/d) was given in a tapering dose schedule during the first three cycles. Response was assessed by International Working Group criteria. Results Eighty-four patients with myelofibrosis-associated anemia were randomly assigned to the aforementioned treatment arms: 22, 19, 22, and 21, respectively. Response in anemia was documented in 20 patients, including 15 who became transfusion independent. Response rates in the four treatment arms were 23% (95% CI, 5% to 41%), 16% (95% CI, 0% to 33%), 36% (95% CI, 16% to 56%), and 19% (95% CI, 2% to 36%). The corresponding figures for patients receiving ≥ 3 cycles of treatment (n = 62) were 38%, 23%, 40%, and 25%. Response to pomalidomide with or without prednisone was durable (range, 3.2 to 16.9+ months) and significantly better in the absence of leukocytosis (37% v 8%; P = .01); JAK2V617F or cytogenetic status did not affect response. Grade ≥ 3 toxicities were infrequent and included (in each treatment arm) neutropenia (9%; 16%; 5%; 5%), thrombocytopenia (14%; 16%; 9%; 5%), and thrombosis (9%; 5%; 0%; 0%). Conclusion Pomalidomide therapy at 0.5 or 2 mg/d with or without an abbreviated course of prednisone is well tolerated in patients with myelofibrosis and active in the treatment of anemia.
The effect of tissue culture on suture holding strength and degradation in canine tendon
Omae, Hiromichi, Zhao, Cathy , Zobitz, M. E., Moran, Steven L. , Amadio, Peter C. , Sun, Yu Long

Mayo Clinic

Journal of Hand Surgery (European Volume) | July 8, 2009 | Volume: 34 | Issue: 5 | Pages: 643-650

10.1177/1753193409104564 | PMID 19587082 Get It

The purpose of this study was to assess tendon metabolism and suture pull-out strength after simple tendon suture in a tissue culture model. One hundred and twelve flexor digitorum profundus tendons from 28 dogs were cultured for 7, 14, or 21 days with or without a static tensile load. In both groups increased levels of matrix metalloproteinase (MMP) mRNA was noted. Suture pull-out strength did not decrease during tissue culture. While the presence of a static load had no effect on the pull-out strength, it did affect MMP mRNA expression. This tissue culture model could be useful in studying the effect of factors on the tendon-suture interface.
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Greenberg, Peter L. , Sun, Zhuoxin , Miller, Kenneth B., Bennett, John M. , Tallman, Martin S. , Dewald, Gordon W., Paietta, Elisabeth , Jagt, Richard van der , Houston, Jessie G., Thomas, Mary L., Cella, David , Rowe, Jacob M.

Mayo Clinic

Blood | June 29, 2009 | Volume: 114 | Issue: 12 | Pages: 2393-2400

10.1182/blood-2009-03-211797 | PMID 19564636 Get It

Abstract This phase 3 prospective randomized trial evaluated the efficacy and long-term safety of erythropoietin (EPO) with or without granulocyte colony-stimulating factor plus supportive care (SC; n = 53) versus SC alone (n = 57) for the treatment of anemic patients with lower-risk myelodysplastic syndromes. The response rates in the EPO versus SC alone arms were 36% versus 9.6%, respectively, at the initial treatment step, 47% in the EPO arm, including subsequent steps. Responding patients had significantly lower serum EPO levels (45% vs 5% responses for levels < 200 mU/mL vs ≥ 200 mU/mL) and improvement in multiple quality-of-life domains. With prolonged follow-up (median, 5.8 years), no differences were found in overall survival of patients in the EPO versus SC arms (median, 3.1 vs 2.6 years) or in the incidence of transformation to acute myeloid leukemia (7.5% and 10.5% patients, respectively). Increased survival was demonstrated for erythroid responders versus nonresponders (median, 5.5 vs 2.3 years). Flow cytometric analysis showed that the percentage of P-glycoprotein+ CD34+ marrow blasts was positively correlated with longer overall survival. In comparison with SC alone, patients receiving EPO with or without granulocyte colony-stimulating factor plus SC had improved erythroid responses, similar survival, and incidence of acute myeloid leukemia transformation.
P2‐107: Intracranial Atherosclerosis as a contributing factor to Alzheimer's disease Dementia
Kokjohn, Tyler A., Maarouf, Chera L., Sabbagh, Marwan N. , Bëlohlávek, Marek , Garami, Zsolt , Beach, Thomas G., Roher, Alex E.

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_10 | Pages: No page available

10.1016/j.jalz.2009.04.418 Get It

P2‐106: Echocardiography vortex formation time reveal cardiac diastolic transmitral flow dysfunction in Alzheimer's disease patients
Roher, Alex E., Bëlohlávek, Marek , Maarouf, Chera L., Kokjohn, Tyler A., Garami, Zsolt , Beach, Thomas G., Sabbagh, Marwan Noel

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_10 | Pages: No page available

10.1016/j.jalz.2009.04.417 Get It

Fine Mapping of Chromosome 6q23-25 Region in Familial Lung Cancer Families Reveals RGS17 as a Likely Candidate Gene
You, Ming , Wang, Daolong, Liu, Pengyuan , Vikis, Haris G., James, Michael A. , Wang, Yian , Jia, Dongmei , Wen, Weidong, Sun, Zhifu , Pinney, Susan M. , Zheng, Wei , Shu, Xiao‐Ou , Long, Jirong , Gao, Yu-Tang, Xiang, Yong-Bing , Chow, Wong‐Ho , Rothman, Nat, Petersen, Gloria M. , Cunningham, Julie M. , Wiest, Jonathan S., Fain, Pamela R., Schwartz, Ann G. , Girard, Luc , Gazdar, Adi, Gaba, Colette , Rothschild, Henry, Mandal, Diptasri , Coons, Teresa, Lee, Juwon , Kupert, Elena, Seminara, Daniela, Bailey‐Wilson, Joan E. , Anderson, Marshall W., Lü, Yan , Wang, Min , Chen, Qiong , Liu, Yan , Yang, Ping , Andrade, Mariza de , Wu, Yanhong , Minna, John Dorrance , Amos, Christopher I. , Sun, Zhifu , Wilson, Richard K , Shu, Xiao-Ou , Zheng, Wei , Pinney, Susan M

Mayo Clinic

Clinical Cancer Research | April 7, 2009 | Volume: 15 | Issue: 8 | Pages: 2666-2674

10.1158/1078-0432.ccr-08-2335 | PMID 19351763 Get It

Abstract Purpose: We have previously mapped a major susceptibility locus influencing familial lung cancer risk to chromosome 6q23-25. However, the causal gene at this locus remains undetermined. In this study, we further refined this locus to identify a single candidate gene, by fine mapping using microsatellite markers and association studies using high-density single nucleotide polymorphisms (SNP). Experimental Design: Six multigenerational families with five or more affected members were chosen for fine-mapping the 6q linkage region using microsatellite markers. For association mapping, we genotyped 24 6q-linked cases and 72 unrelated noncancer controls from the Genetic Epidemiology of Lung Cancer Consortium resources using the Affymetrix 500K chipset. Significant associations were validated in two independent familial lung cancer populations: 226 familial lung cases and 313 controls from the Genetic Epidemiology of Lung Cancer Consortium, and 154 familial cases and 325 controls from Mayo Clinic. Each familial case was chosen from one high-risk lung cancer family that has three or more affected members. Results: A region-wide scan across 6q23-25 found significant association between lung cancer susceptibility and three single nucleotide polymorphisms in the first intron of the RGS17 gene. This association was further confirmed in two independent familial lung cancer populations. By quantitative real-time PCR analysis of matched tumor and normal human tissues, we found that RGS17 transcript accumulation is highly and consistently increased in sporadic lung cancers. Human lung tumor cell proliferation and tumorigenesis in nude mice are inhibited upon knockdown of RGS17 levels. Conclusion: RGS17 is a major candidate for the familial lung cancer susceptibility locus on chromosome 6q23-25.
Bladder Cancer–Associated Gene Expression Signatures Identified by Profiling of Exfoliated Urothelia
Rosser, Charles J. , Liu, Li , Villicana, Patrick, McCullers, Molly, Porvasnik, Stacy, Parker, Alexander S. , Goodison, Steve , Sun, Yijun , Young, Paul R.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 10, 2009 | Volume: 18 | Issue: 2 | Pages: 444-453

10.1158/1055-9965.epi-08-1002 | PMID 19190164 Get It

Abstract Bladder cancer is the fifth most commonly diagnosed malignancy in the United States and one of the most prevalent worldwide. It harbors a probability of recurrence of &gt;50%; thus, rigorous, long-term surveillance of patients is advocated. Flexible cystoscopy coupled with voided urine cytology is the primary diagnostic approach, but cystoscopy is an uncomfortable, invasive procedure and the sensitivity of voided urine cytology is poor in all but high-grade tumors. Thus, improvements in noninvasive urinalysis assessment strategies would benefit patients. We applied gene expression microarray analysis to exfoliated urothelia recovered from bladder washes obtained prospectively from 46 patients with subsequently confirmed presence or absence of bladder cancer. Data from microarrays containing 56,000 targets was subjected to a panel of statistical analyses to identify bladder cancer-associated gene signatures. Hierarchical clustering and supervised learning algorithms were used to classify samples on the basis of tumor burden. A differentially expressed geneset of 319 gene probes was associated with the presence of bladder cancer (P &lt; 0.01), and visualization of protein interaction networks revealed vascular endothelial growth factor and angiotensinogen as pivotal factors in tumor cells. Supervised machine learning and a cross-validation approach were used to build a 14-gene molecular classifier that was able to classify patients with and without bladder cancer with an overall accuracy of 76%. Our results show that it is possible to achieve the detection of bladder cancer using molecular signatures present in exfoliated tumor urothelia. Further investigation and validation of the cancer-associated profiles may reveal important biomarkers for the noninvasive detection and surveillance of bladder cancer. (Cancer Epidemiol Biomarkers Prev 2009;18(2):444–53)
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease
Roher, Alex E., Esh, Chera L., Kokjohn, Tyler A., Castaño, Eduardo M., Vickle, Gregory D. Van, Kalback, Walter M., Patton, Rebekah , Luehrs, Dean C., Daugs, Ian D., Kuo, Yu‐Min , Emmerling, Mark R., Soares, Holly , Quinn, Joseph F. , Kaye, Jeffrey , Connor, Donald J., Silverberg, Nina, Seward, James D., Beach, Thomas G. , Adler, Charles H. , Sabbagh, Marwan Noel , Quinn, Joseph F

Mayo Clinic

Alzheimer's & Dementia | December 31, 2008 | Volume: 5 | Issue: 1 | Pages: 18-29

10.1016/j.jalz.2008.10.004 | PMID 19118806 Get It

BackgroundWe evaluated the amounts of amyloid beta (Aβ)) peptides in the central nervous system (CNS) and in reservoirs outside the CNS and their potential impact on Aβ plasma levels and Alzheimer's disease (AD) pathology.MethodsAmyloid β levels were measured in (1) the plasma of AD and nondemented (ND) controls in a longitudinal study, (2) the plasma of a cohort of AD patients receiving a cholinesterase inhibitor, and (3) the skeletal muscle, liver, aorta, platelets, leptomeningeal arteries, and in gray and white matter of AD and ND control subjects.ResultsPlasma Aβ levels fluctuated over time and among individuals, suggesting continuous contributions from brain and peripheral tissues and associations with reactive circulating proteins. Arteries with atherosclerosis had larger amounts of Aβ40 than disease‐free vessels. Inactivated platelets contained more Aβ peptides than activated ones. Substantially more Aβ was present in liver samples from ND patients. Overall, AD brain and skeletal muscle contained increased levels of Aβ.ConclusionsEfforts to use plasma levels of Aβ peptides as AD biomarkers or disease‐staging scales have failed. Peripheral tissues might contribute to both the circulating amyloid pool and AD pathology within the brain and its vasculature. The wide spread of plasma Aβ values is also due in part to the ability of Aβ to bind to a variety of plasma and membrane proteins. Sources outside the CNS must be accounted for because pharmacologic interventions to reduce cerebral amyloid are assessed by monitoring Aβ plasma levels. Furthermore, the long‐range impact of Aβ immunotherapy on peripheral Aβ sources should also be considered.
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation
Ringdén, Olle , Pavletic, Steven Z. , Anasetti, Claudio , Wang, Tao , Antin, Joseph H. , Bartolomeo, Paolo Di , Bolwell, Brian J., Bredeson, Christopher , Cairo, Mitchell S. , Gupta, Vikas , Hahn, Theresa , Hale, Gregory A., Halter, Jörg , Jagasia, Madan , Litzow, Mark R. , Marks, David I. , Cowan, Morton J. , Petersdorf, Effie W. , Russell, James A. , Schiller, Gary J. , Schouten, Harry C. , Verdonck, Leo F. , Horowitz, Mary M. , Arora, Mukta , Barrett, A. John , Wang, Dan , Gale, Robert Peter , Locatelli, Franco , McCarthy, Philip L. , Spellman, Stephen R. , Wingard, John R. , Halter, Joerg , Ringden, Olov , Gupta, Vikas

Mayo Clinic

Blood | December 5, 2008 | Volume: 113 | Issue: 13 | Pages: 3110-3118

10.1182/blood-2008-07-163212 | PMID 19059878 Get It

AbstractDo some patients benefit from an unrelated donor (URD) transplant because of a stronger graft-versus-leukemia (GVL) effect? We analyzed 4099 patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML) undergoing a myeloablative allogeneic hematopoietic cell transplantation (HCT) from an URD (8/8 human leukocyte antigen [HLA]–matched, n = 941) or HLA-identical sibling donor (n = 3158) between 1995 and 2004 reported to the CIBMTR. In the Cox regression model, acute and chronic GVHD were added as time-dependent variables. In multivariate analysis, URD transplant recipients had a higher risk for transplantation-related mortality (TRM; relative risk [RR], 2.76; P < .001) and relapse (RR, 1.50; P < .002) in patients with AML, but not ALL or CML. Chronic GVHD was associated with a lower relapse risk in all diagnoses. Leukemia-free survival (LFS) was decreased in patients with AML without acute GVHD receiving a URD transplant (RR, 2.02; P < .001) but was comparable to those receiving HLA-identical sibling transplants in patients with ALL and CML. In patients without GVHD, multivariate analysis showed similar risk of relapse but decreased LFS for URD transplants for all 3 diagnoses. In conclusion, risk of relapse was the same (ALL, CML) or worse (AML) in URD transplant recipients compared with HLA-identical sibling transplant recipients, suggesting a similar GVL effect.
Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigen–Identical Sibling Transplants for Adults With Leukemia
Hahn, Theresa , Zhang, Mei-Jie , Wang, Dan , Arora, Mukta , Frangoul, Haydar , Hale, Gregory A., Horan, John , Isola, Luis , Rood, Jon J. van, Gupta, Vikas , Halter, Joerg , Reddy, Vijay , Tiberghien, Pierre , Litzow, Mark R. , Anasetti, Claudio , Pavletic, Stephen, Ringdén, Olle , Halter, Jörg , McCarthy, Philip L. , Gale, Robert Peter , Maziarz, Richard Thomas , Ringden, Olov , Gupta, Vikas

Mayo Clinic

Journal of Clinical Oncology | November 4, 2008 | Volume: 26 | Issue: 35 | Pages: 5728-5734

10.1200/jco.2008.17.6545 | PMID 18981462 Get It

Purpose Acute graft-versus-host disease (GVHD) causes substantial morbidity and mortality after human leukocyte antigen (HLA)-identical sibling transplants. No large registry studies of acute GVHD risk factors have been reported in two decades. Risk factors may have changed in this interval as transplant-related techniques have evolved. Patients and Methods Acute GVHD risk factors were analyzed in 1,960 adults after HLA-identical sibling myeloablative transplant for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or chronic myeloid leukemia (CML) reported by 226 centers worldwide to the Center for International Blood and Marrow Transplant Research from 1995 to 2002. Outcome was measured as time from transplant to onset of grade 2 to 4 acute GVHD, with death without acute GVHD as a competing risk. Results Cumulative incidence of grade 2 to 4 acute GVHD was 35% (95% CI, 33% to 37%). In multivariable analyses, factors significantly associated with grade 2 to 4 acute GVHD were cyclophosphamide + total-body irradiation versus busulfan + cyclophosphamide (relative risk [RR] = 1.4; P < .0001), blood cell versus bone marrow grafts in patients age 18 to 39 years (RR = 1.43; P = .0023), recipient age 40 and older versus age 18 to 39 years receiving bone marrow grafts (RR = 1.44; P = .0005), CML versus AML/ALL (RR = 1.35; P = .0003), white/Black versus Asian/Hispanic race (RR = 1.54; P = .0003), Karnofsky performance score less than 90 versus 90 to 100 (RR = 1.27; P = .014), and recipient/donor cytomegalovirus-seronegative versus either positive (RR = 1.20; P = .04). Stratification by disease showed the same significant predictors of grade 2 to 4 acute GVHD for CML; however, KPS and cytomegalovirus serostatus were not significant predictors for AML/ALL. Conclusion This analysis confirmed several previously reported risk factors for grade 2 to 4 acute GVHD. However, several new factors were identified whereas others are no longer significant. These new data may facilitate individualized risk estimates and raise several interesting biologic questions.